SCHEMBL2069503

SCHEMBL2069503

COCc1ncc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCC3)nc2C)c(=O)n4C)cc1OC(C)C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ATM Q13315 17/20 0.48
ATR Q13535 10/20 0.48
PIK3CA P42336 4/20 0.42
MTOR P42345 4/20 0.42
PIK3CD O00329 3/20 0.40
PIK3CB P42338 3/20 0.40
PIK3CG P48736 3/20 0.40
CSNK2A2 P19784 1/20 0.40
FECH P22830 1/20 0.40
CLK1 P49759 1/20 0.40
GSK3A P49840 1/20 0.40
DYRK1A Q13627 1/20 0.40
MELK Q14680 1/20 0.40
MYLK3 Q32MK0 1/20 0.40
PIK3C3 Q8NEB9 1/20 0.40
PIP4K2C Q8TBX8 1/20 0.40
TP53RK Q96S44 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067596 0.93 ATM (0.49) ATMATRPIK3CAMTORPIK3CD
SCHEMBL2068680 0.91 ATM (0.46) ATMATRPIK3CAMTORPIK3CD
SCHEMBL2068198 0.90 ATM (0.46) ATMATRPIK3CAMTORPIK3CD
SCHEMBL12985852 0.85 ATM (0.62) ATMATRPIK3CAMTORPIK3CD
SCHEMBL3514985 0.84 ATM (0.49) ATMATRPIK3CAMTORPIK3CD
SCHEMBL2068160 0.84 ATM (0.45) ATMATRPIK3CAMTORPIK3CD
SCHEMBL2068071 0.84 ATM (0.45) ATMATRPIK3CAMTORPIK3CD
SCHEMBL3516614 0.83 ATM (0.47) ATMATRPIK3CAMTORPIK3CD
SCHEMBL2067603 0.81 ATM (0.51) ATMATRPIK3CAMTORPIK3CD
SCHEMBL2069377 0.80 ATM (0.41) ATMATRPIK3CAMTORPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP claimed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO claimed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US claimed
EP-2438063-A1 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-04-11 EP disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 ATM 1084/4885ATR 2685/4885PIK3CA 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.